Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kubalek, I.
Right arrow Articles by Thomas, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kubalek, I.
Right arrow Articles by Thomas, M.
Related Collections
Right arrow Spinal Pain
Right arrow Psychology: Measurement and Management of Pain
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 1394-1397
© 2001 British Society for Rheumatology

Original Papers

Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases

I. Kubalek, O. Fain, J. Paries, A. Kettaneh and M. Thomas

Service de Médecine Interne, Hôpital Jean Verdier, Assistance Publique—Hôpitaux de Paris, Université Paris Nord, UPRES Recherche Clinique et Thérapeutique, Avenue du 14 Juillet, 93140 Bondy, France

Objective. To evaluate the efficacy of treatment with pamidronate in reflex sympathetic dystrophy (RSD) refractory to previous treatment.

Methods. We studied the response (disappearance of pain and functional improvement) to pamidronate (60 mg/day for 3 days) in 29 patients with RSD refractory to previous treatment for at least 14 days.

Results. On day 45, complete pain disappearance was observed in 86.2% of patients and functional improvement in 70%. The mean delay until the pain disappeared was 20±14 days and the delay until functional improvement was observed was 29±18 days. The mean delay of functional improvement was shorter in patients with post-traumatic RSD. Multivariate analysis did not reveal any factor predictive of response to treatment. Six (20.7%) patients suffered from side-effects (fever, diarrhoea).

Conclusion. Pamidronate appeared to be effective in the treatment of refractory RSD; however, these results need to be confirmed by a controlled placebo study.

KEY WORDS: Pamidronate, Bisphosphonates, Reflex sympathetic dystrophy, Algodystrophy, Complex regional pain syndrome (CRPS) type I.

Correspondence to: O. Fain.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H. Amital, Y. H. Applbaum, S. Aamar, N. Daniel, and A. Rubinow
SAPHO syndrome treated with pamidronate: an open-label study of 10 patients
Rheumatology, May 1, 2004; 43(5): 658 - 661.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.